Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism

Increased glutathione (GSH) and thioredoxin (Trx) metabolism are mechanisms that are widely implicated in resistance of cancer cells to chemotherapy. The current study determined if simultaneous inhibition of GSH and Trx metabolism enhanced cell killing of human head and neck squamous cell carcinoma (HNSCC) cells by a mechanism involving oxidative stress. Inhibition of GSH and Trx metabolism with buthionine sulfoximine (BSO) and auranofin (AUR), respectively, induced significant decreases in clonogenic survival compared to either drug alone in FaDu, Cal-27 and SCC-25 HNSCC cells in vitro and in vivo in Cal-27 xenografts. BSO+AUR significantly increased glutathione and thioredoxin oxidation and suppressed peroxiredoxin activity in vitro. Pre-treatment with N-acetylcysteine completely reversed BSO+AUR-induced cell killing in FaDu and Cal-27 cells, while catalase and selenium supplementation only inhibited BSO+AUR-induced cell killing in FaDu cells. BSO+AUR decreased caspase 3/7 activity in HNSCC cells and significantly reduced the viability of both Bax/Bak double knockout (DKO) and DKO-Bax reconstituted hematopoietic cells suggesting that necrosis was involved. BSO+AUR also significantly sensitized FaDu, Cal-27, SCC-25 and SQ20B cells to cell killing induced by the EGFR inhibitor Erlotinib in vitro. These results support the conclusion that simultaneous inhibition of GSH and Trx metabolism pathways induces oxidative stress and clonogenic killing in HNSCCs and this strategy may be useful in sensitizing HNSCCs to EGFR inhibitors.

[1]  W. Watson,et al.  Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. , 2012, Free radical biology & medicine.

[2]  D. Spitz,et al.  Enhancement of Carboplatin-Mediated Lung Cancer Cell Killing by Simultaneous Disruption of Glutathione and Thioredoxin Metabolism , 2011, Clinical Cancer Research.

[3]  Elias S. J. Arnér,et al.  Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors. , 2011, Free radical biology & medicine.

[4]  G. Bornkamm,et al.  Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. , 2010, Cancer research.

[5]  K. Brown,et al.  Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin , 2010, FEBS letters.

[6]  D. Greetham,et al.  The Thioredoxin-Thioredoxin Reductase System Can Function in Vivo as an Alternative System to Reduce Oxidized Glutathione in Saccharomyces cerevisiae* , 2009, The Journal of Biological Chemistry.

[7]  L. Szekely,et al.  High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. , 2009, Free radical biology & medicine.

[8]  D. Spitz,et al.  Inhibition of Glutathione and Thioredoxin Metabolism Enhances Sensitivity to Perifosine in Head and Neck Cancer Cells , 2009, Journal of oncology.

[9]  M. Fricker,et al.  The NADPH-dependent thioredoxin system constitutes a functional backup for cytosolic glutathione reductase in Arabidopsis , 2009, Proceedings of the National Academy of Sciences.

[10]  A. Corti,et al.  Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. , 2009, Anticancer research.

[11]  K. Brown,et al.  The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. , 2008, Biochemical pharmacology.

[12]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[13]  J. Reichheld,et al.  Inactivation of Thioredoxin Reductases Reveals a Complex Interplay between Thioredoxin and Glutathione Pathways in Arabidopsis Development[W] , 2007, The Plant Cell Online.

[14]  A. Maity,et al.  Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation , 2007, Cancer biology & therapy.

[15]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[16]  M. Ozsahin,et al.  The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications , 2006, Radiation oncology.

[17]  A. Folda,et al.  Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase , 2005, Free radical research.

[18]  B. Morgan,et al.  Oxidation of a Eukaryotic 2-Cys Peroxiredoxin Is a Molecular Switch Controlling the Transcriptional Response to Increasing Levels of Hydrogen Peroxide* , 2005, Journal of Biological Chemistry.

[19]  S. Kang,et al.  Activity assay of mammalian 2-cys peroxiredoxins using yeast thioredoxin reductase system. , 2005, Analytical biochemistry.

[20]  Chi Li,et al.  Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis , 2005, Cell.

[21]  W. Hong,et al.  Focus on head and neck cancer. , 2004, Cancer cell.

[22]  Dean P. Jones,et al.  Redox Potential of Human Thioredoxin 1 and Identification of a Second Dithiol/Disulfide Motif* , 2003, Journal of Biological Chemistry.

[23]  Yong J. Lee,et al.  Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. , 2003, The Biochemical journal.

[24]  S. Korsmeyer,et al.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. , 2003, Cancer research.

[25]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[26]  S. Berners‐Price,et al.  Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria , 2002 .

[27]  J. Irish,et al.  Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line , 2002, Cell Death and Differentiation.

[28]  P. Sancho,et al.  Effect of Glutathione Depletion on Antitumor Drug Toxicity (Apoptosis and Necrosis) in U-937 Human Promonocytic Cells , 2001, The Journal of Biological Chemistry.

[29]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[30]  J. Hayes,et al.  Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. , 1999, Free radical research.

[31]  C. Shaw.  Gold-Based Therapeutic Agents , 1999 .

[32]  B. Schummer,et al.  Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins , 1999, Urological Research.

[33]  H. Bailey.  L-S,R-buthionine sulfoximine: historical development and clinical issues. , 1998, Chemico-biological interactions.

[34]  D. Mahvi,et al.  Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. , 1997, Journal of the National Cancer Institute.

[35]  R. Roberts,et al.  Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts , 1995, Journal of cellular physiology.

[36]  J. Shah,et al.  Treatment of cancer of the head and neck , 1995, CA: a cancer journal for clinicians.

[37]  R. Ozols,et al.  Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. , 1995, Cancer research.

[38]  R. Ozols,et al.  Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. , 1993, Cancer research.

[39]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[40]  J. Phillips,et al.  Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: The significance of increased catalase activity and total glutathione in hydrogen peroxide‐resistant fibroblasts , 1993, Journal of cellular physiology.

[41]  R. Ozols,et al.  Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. , 1992, Journal of the National Cancer Institute.

[42]  H. Benn,et al.  Whole body elimination routes of gold in humans after a single-dose application of the antirheumatic Auranofin , 1990, Biological Trace Element Research.

[43]  R. Roberts,et al.  Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in H2O2-resistant cell lines. Do aldehydic by-products of lipid peroxidation contribute to oxidative stress? , 1990, The Biochemical journal.

[44]  H. Löffler,et al.  Pharmacokinetics of auranofin a single dose study in man. , 1990, The Journal of rheumatology.

[45]  J. Mitchell,et al.  The role of glutathione in radiation and drug induced cytotoxicity. , 1987, The British journal of cancer. Supplement.

[46]  R. Weichselbaum,et al.  Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Blocka.  Auranofin versus injectable gold. Comparison of pharmacokinetic properties. , 1983, The American journal of medicine.

[48]  R. Burk,et al.  Glutathione peroxidase activity in selenium-deficient rat liver. , 1976, Biochemical and biophysical research communications.

[49]  R. Mavis,et al.  Purification and subunit structure of glutathione reductase from bakers' yeast. , 1968, The Journal of biological chemistry.

[50]  R. Hondal,et al.  Thioredoxin reductase. , 2000, The Biochemical journal.

[51]  J. Whang‐Peng,et al.  Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. , 1995, Oncology research.

[52]  G. Wilding,et al.  Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[54]  H. Aebi,et al.  Catalase in vitro. , 1984, Methods in enzymology.